Is PET superior to MRI in the pretherapeutic evaluation of head and neck squamous celi carcinoma?

Abstract

Objectives: This study was designed to compare the effectiveness of positron emission tomography PET and magnetic resonance imaging MRI in the prethera­ peutic staging of squamous celi carcinoma SCC of the head and neck.Patients and Methods: The study included 34 consecu- tive patients 27 males, 7 females; mean age 61 years; range 42 to 82 years with SCC of the head and neck. Ali thepatientsunderwentwholebody[18Flfluorodeoxyglucose FDG -PET and MRI seans for pretherapeutic evaluation.Diagnoses were confirmed by histopathologic examina- tion of endoscopic biopsy specimens.Results: The sites of the primary tumors were the oro- pharynx n=15, 44% , larynx n=10, 29% , hypopharynx n=8, 24% , and nasopharynx n=1, 3% . Surgery was the treatment of choice in 20 patients 59% , ineluding 23 neck disseetions. Fourteen patients 41% were treated with radiochemotherapy. Both PET and MRI were able to detect the primary tumor in 33 cases 97% . İn two patients 6% , PET was able to detect distant metastases in the lung and iliac bone, ali of which were confirmed by biop- sies. Seven neck specimens 30% showed lymph node metastasis. Sensitivity and specificity rates for deteetion of lymph node metastasis were 100% and 87.5% for PET, and 85.7% and 87.5% for MRI, respeetively.Conclusion: Although PET seems to be superior to MRI in deteeting nodal disease and distant metastases, it is stili early to recommend it as a primary tool for pre­ therapeutic evaluation of head and neck cancers due to its limited availability and higher cost.

Keywords

• Carcinoma, squamous cell/radionuclide imaging, head and neck neoplasms, magnetic resonance imaging, neoplasm staging, positron-emission tomography

Baş-boyun bölgesi yassı hücreli karsinomlarm tedavi öncesi değerlendirilmesinde PET MRG'den üstün müdür?

Abstract

Amaç: Bu çalışmada, yassı hücreli baş-boyun karsinomlarının tedavi öncesi değerlendirilmesinde pozitron emisyon tomografisi PET ve manyetik rezonans görüntülemenin MRG etkinliğinin karşılaştırılması amaçlandı.Hastalar ve Yöntemler: Çalışmaya baş-boyun bölgesi yassı hücreli karsinomu olan 34 ardışık hasta alındı. Tüm hastalar tedavi öncesinde tüm vücut [18F]florodeoksiglukoz FDG -PET ve MRG görüntülemesi ile değerlendirildi. Tüm hastaların tanıları endoskopik biyopsi örneklerinin histopatolojik değerlendirilmesi ile doğrulandı.Bulgular: Primer tümörlerin yerleşimleri şöyleydi: orofarenks n=15, %44 , larenks n=10, %29 , hipofarenks n=8, %24 , nazofarenks n=1, %3 . Yirmi hastada %59 cerrahi tedavi uygulandı; bu hastalara 23 boyun diseksiyonu yapıldı. On dört hastada %41 radyoterapi uygulandı. Her iki görüntüleme yöntemi de 33 hastada %97 primer tümörü doğru olarak saptayabildi. Ayrıca, PET yardımıyla iki hastada %6 akciğer ve iliyak kemikte uzak metastazlar saptandı; bunların hepsi biyopsi sonuçlarıyla doğrulandı. Boyun diseksiyonlarının yedisinde %30 lenf nodu metastazı vardı. Lenf nodu tutulumunun gösterilmesinde duyarlılık ve özgüllük oranları PET için sırasıyla %100 ve %87.5, MRG için %85.7 ve %87.5 bulundu.Sonuç: Nodal hastalığın ve uzak metastazların saptanmasında PET MRGʼden daha üstün görünmesine rağmen, bu yöntemi baş-boyun kanserlerinin tedavi öncesi değerlendirilmesinde esas araç olarak önermek sınırlı kullanımı ve yüksek maliyeti nedeniyle erkendir

Keywords

• Yası hücreli karsinom/radyonüklid görüntüleme, baş-boyun tümörleri, manyetik rezonans görüntüleme, tümör evrelemesi, pozitron emisyon tomografisi

References

1. Schifter T, Hoffman JM, Hanson MW, Donnal JF, Boyko OB, Schold SC, et al. Serial FDG-PET in the management of primary brain tumors. J Comput Assist Tomogr 1993;17:509-16.
2. Patronas NJ, Di Chiro G, Kufta C, Bairamian D, Kornblith PL, Simon R, et al. Prediction of survival in glioma patients by means of positron emission tomog- raphy. J Neurosurg 1985;62:816-22.
3. Gupta NC, Frank AR, Dewan NA, Redepenning LS, Rothberg ML, Mailliard JA, et al. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F- 18]-fluoro-2-deoxy-D-glucose. Radiology 1992;184:441-4.
4. Patz EF Jr, Lowe VJ, Hoffman JM, Paine SS, Burrowes P, Coleman RE, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scan- ning. Radiology 1993;188:487-90.
5. Minn H, Soini I. [18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med 1989;15:61-6.
6. Strauss LG, Conti PS. The applications of PET in clini- cal oncology. J Nucl Med 1991;32:623-48.
7. Teknos TN, Rosenthal EL, Lee D, Taylor R, Marn CS. Positron emission tomography in the evaluation of stage III and IV head and neck cancer. Head Neck 2001; 23:1056-60.
8. Stoeckli SJ, Steinert H, Pfaltz M, Schmid S. Is there a role for positron emission tomography with 18F-fluo- rodeoxyglucose in the initial staging of nodal negative oral and oropharyngeal squamous cell carcinoma. Head Neck 2002;24:345-9.

9. Hanasono MM, Kunda LD, Segall GM, Ku GH, Terris DJ. Uses and limitations of FDG positron emission tomography in patients with head and neck cancer. Laryngoscope 1999;109:880-5.
10. Di Martino E, Nowak B, Hassan HA, Hausmann R, Adam G, Buell U, et al. Diagnosis and staging of head and neck cancer: a comparison of modern imaging modalities (positron emission tomography, computed tomography, color-coded duplex sonography) with panendoscopic and histopathologic findings. Arch Otolaryngol Head Neck Surg 2000;126:1457-61.
11. Snow GB, Annyas AA, van Slooten EA, Bartelink H, Hart AA. Prognostic factors of neck node metastasis. Clin Otolaryngol Allied Sci 1982;7:185-92.
12. Grandi C, Alloisio M, Moglia D, Podrecca S, Sala L, Salvatori P, et al. Prognostic significance of lymphatic spread in head and neck carcinomas: therapeutic implications. Head Neck Surg 1985;8:67-73.
13. Lonneux M, Lawson G, Ide C, Bausart R, Remacle M, Pauwels S. Positron emission tomography with fluo- rodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Laryngoscope 2000;110:1493-7.
14. Farber LA, Benard F, Machtay M, Smith RJ, Weber RS, Weinstein GS, et al. Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18F-fluoro-2-deoxy-D-glucose positron emis- sion tomography. Laryngoscope 1999;109:970-5.
15. Stuckensen T, Kovacs AF, Adams S, Baum RP. Staging of the neck in patients with oral cavity squamous cell carcinomas: a prospective comparison of PET, ultra- sound, CT and MRI. J Craniomaxillofac Surg 2000;28: 319-24.
16. Hannah A, Scott AM, Tochon-Danguy H, Chan JG, Akhurst T, Berlangieri S, et al. Evaluation of 18F-fluo- rodeoxyglucose positron emission tomography and computed tomography with histopathologic correla- tion in the initial staging of head and neck cancer. Ann Surg 2002;236:208-17.
17. Kresnik E, Mikosch P, Gallowitsch HJ, Kogler D, Wiesser S, Heinisch M, et al. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods. Eur J Nucl Med 2001;28:816-21.
18. Laubenbacher C, Saumweber D, Wagner-Manslau C, Kau RJ, Herz M, Avril N, et al. Comparison of fluo- rine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med 1995;36:1747-57.
19. Wong WL, Chevretton EB, McGurk M, Hussain K, Davis J, Beaney R, et al. A prospective study of PET- FDG imaging for the assessment of head and neck squamous cell carcinoma. Clin Otolaryngol Allied Sci 1997;22:209-14.
20. Hanasono MM, Kunda LD, Segall GM, Ku GH, Terris DJ. Uses and limitations of FDG positron emission tomography in patients with head and neck cancer. Laryngoscope 1999;109:880-5.
21. Manolidis S, Donald PJ, Volk P, Pounds TR. The use of positron emission tomography scanning in occult and recurrent head and neck cancer. Acta Otolaryngol Suppl 1998;534:1-11.